Why the study?
Does the presence of inducible ventricular tachycardia during antiarrhythmic drug therapy predict worse clinical outcomes compared to non-inducible VT, in the absence of frequent spontaneous ventricular ectopy?
Does the presence of inducible ventricular tachycardia during antiarrhythmic drug therapy predict worse clinical outcomes compared to non-inducible VT, in the absence of frequent spontaneous ventricular ectopy?
Answers are grounded in this paper and cite their sources.
Highlights that suppression of spontaneous ventricular ectopy on Holter may be a sufficient marker of antiarrhythmic drug efficacy even if VT remains inducible on EP study.
IN this issue, Kim and colleagues report interesting results in patients with life-threatening ventricular tachyarrhythmias who underwent both ambulatory (Holter) electrocardiographic monitoring and electrophysiologic study (programmed electrical stimulation) to test the efficacy of antiarrhythmic drugs.1 They observed that the clinical outcome in patients who continued to have inducible ventricular tachycardia while receiving drug therapy was as good as the outcome in those who did not, as long as the former did not have frequent spontaneous ventricular ectopy during Holter monitoring. Their observations provide an opportunity to discuss the advantages and limitations of these two techniques for evaluating drug therapy for . . .
No takes yet. Share an insight, caveat, or question.
Anderson et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: